What is it about?
Genetic variants contribute to statins' therapeutic variability. The 'G' allele in SCAP and SREBF-1a is significant predictor of rosuvastatin response in metabolic syndrome patients.
Featured Image
Why is it important?
No data is available in Saudi population which is genetically different from the main studied populations of the world. In addition, rosuvastatin pharmacogenetics is less explored, that too in complex diseases like metabolic syndrome
Perspectives
This article is of interest to myriad readership including clinical research scholars, clinicians, and basic scientists.The study may be replicated in less studied populations with other similar drugs
Misbahuddin Rafeeq
King Abdulaziz University
Read the Original
This page is a summary of: Effect of genetic polymorphisms in SREBF–SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients, Pharmacogenomics, February 2018, Future Medicine,
DOI: 10.2217/pgs-2017-0181.
You can read the full text:
Contributors
The following have contributed to this page
